{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T04:50:35Z","timestamp":1764996635671,"version":"3.44.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum D\u00fcsseldorf. Anstalt \u00f6ffentlichen Rechts"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>MDS patients show a heterogenous prognosis which can be stratified by the IPSS-R in order to derive therapeutic implications. Based on 618 patients with myelodysplastic neoplasms belonging to the cytogenetic intermediate-risk group according to IPSS-R, we show that this group is heterogeneous in terms of overall survival and cumulative risk of AML. The group can be reorganized into subgroups according to their prognostic impact. A small subgroup of patients with isolated -X or der(1;7) can be regarded as very-low-risk patients with a median survival time of 112 months and a cumulative AML progression rate of 9% after 2 years. A larger group of patients with either diverse aberrations of one chromosome or -Y\u2009+\u2009one additional aberration shows a benign course of the disease with a median survival time of 46 months and a cumulative AML progression rate of 26% after 2 years. A very large group of patients presenting with either +\u20098, +19, i(17q), +\u200921, +mar, del(9q), +\u20098 plus one other aberration, or del(7q) have a poor prognosis with a median survival time of 26 months and a cumulative AML progression rate of 32% after 2 years. In a very small set of patients with trisomy 11 the course of disease was similar to very-high-risk patients with a median survival time of 17 months only and a cumulative AML progression rate of 100% after 2 years. These findings could lead to a refinement of prognostic scoring systems such as the IPSS-R and the IPSS-M.<\/jats:p>","DOI":"10.1007\/s00277-025-06443-6","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T04:44:04Z","timestamp":1749444244000},"page":"3251-3259","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Refinement of intermediate-risk Karyotypes\u00a0according to the IPSS-R in patients with myelodysplastic neoplasms (MDS)"],"prefix":"10.1007","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5893-2298","authenticated-orcid":false,"given":"K.","family":"Nachtkamp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Kasprzak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Strupp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Hildebrandt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Pfeilst\u00f6cker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Valent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Blum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Giagounidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"G\u00f6tze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Flatten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Kobbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Haase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Gattermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Germing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,9]]},"reference":[{"key":"6443_CR1","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","volume":"89","author":"P Greenberg","year":"1997","unstructured":"Greenberg P, Cox C, LeBeau MM et al (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079\u20132088. https:\/\/doi.org\/10.1182\/blood.V89.6.2079. Erratum in: Blood 1998;91(3):1100","journal-title":"Blood"},{"key":"6443_CR2","doi-asserted-by":"publisher","unstructured":"Malcovati L, Germing U, Kuendgen A et al (2007) Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25:3503\u20133510. https:\/\/doi.org\/10.1200\/jco.2006.08.5696.","DOI":"10.1200\/jco.2006.08.5696"},{"key":"6443_CR3","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","volume":"120","author":"PL Greenberg","year":"2012","unstructured":"Greenberg PL, Tuechler H, Schanz J et al (2012) Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120:2454\u20132465. https:\/\/doi.org\/10.1182\/blood-2012-03-420489","journal-title":"Blood"},{"issue":"8","key":"6443_CR4","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1200\/jco.2011.35.6394","volume":"30","author":"J Schanz","year":"2012","unstructured":"Schanz J, T\u00fcchler H, Sole F, Mallo M, Lu\u00f1o E, Cervera J, Granada I, Hildebrandt B, Slovak ML, Ohyashiki K, Steidl C, Fonatsch C, Pfeilst\u00f6cker M, N\u00f6sslinger T, Valent P, Giagounidis A, Aul C, L\u00fcbbert M, Stauder R, Krieger O, Garcia-Manero G, Faderl S, Pierce S, Le Beau MM, Bennett JM, Greenberg P, Germing U, Haase D (2012) New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 30(8):820\u2013829. https:\/\/doi.org\/10.1200\/jco.2011.35.6394","journal-title":"J Clin Oncol"},{"issue":"7","key":"6443_CR5","doi-asserted-by":"publisher","first-page":"EVIDoa2200008","DOI":"10.1056\/EVIDoa2200008","volume":"1","author":"E Bernard","year":"2022","unstructured":"Bernard E, Tuechler H, Greenberg PL, Hasserjian RP, Ossa JA, Nannya Y, Devlin SM, Creignou M, Pinel P, Monnier L, Medina-Martinez JS, Werner Y, J\u00e4dersten M, Germing U, Sanz G, Van de Loosdrecht AA, Kosmider O, Follo MY, Thol F, Zamora L, Feitosa Pinheiro R, Pellagati A, Elias H, Haase D, Ganster C, Ades L, Tobiasson M, Della Porta M, Takaori-Kondo A, Ishikawa T, Chiba S, Kasahara S, Miyasaki Y, Fenaux P, Belickova M, Savona MR, Klimek VM, de Pirez F, Boultwood J, Kotsianidis I, Santini V, Sole F, Platzbecker U, Heuser M, Valent P, Ohyashiki K, Finelli C, Voso MT, Shih LY, Fontenay M, Jansen JH, Cervera J, Gattermann N, Ebert BL, Bejar R, Malcovati L, Cazzola M, Ogawa S, Hellstrom-Lindberg E, Papaemmanuil E (2022) Molecular international prognosis scoring system for myelodysplastic syndromes. NEJM Evid 1(7):EVIDoa2200008. https:\/\/doi.org\/10.1056\/EVIDoa2200008","journal-title":"NEJM Evid"},{"issue":"1","key":"6443_CR6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.leukres.2013.10.013","volume":"38","author":"J Neukirchen","year":"2014","unstructured":"Neukirchen J, Lauseker M, Blum S, Giagounidis A, L\u00fcbbert M, Martino S, Siragusa S, Schlenk RF, Platzbecker U, Hofmann WK, G\u00f6tze K, Palumbo GA, Magrin S, K\u00fcndgen A, Aul C, Hildebrandt B, Hasford J, Kobbe G, Haas R, Germing U (2014) Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multicenter study. Leuk Res 38(1):57\u201364.","journal-title":"Leuk Res"},{"issue":"21","key":"6443_CR7","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1200\/JCO.2012.48.0764","volume":"31","author":"MT Voso","year":"2013","unstructured":"Voso MT, Fenu S, Latagliata R, Buccisano F, Piciocchi A, Aloe-Spiriti MA, Breccia M, Criscuolo M, Andriani A, Mancini S, Niscola P, Naso V, Nobile C, Piccioni AL, D\u2019Andrea M, D\u2019Addosio A, Leone G, Venditti A (2013) Revised international prognostic scoring system (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO prognostic scoring system: validation by the gruppo Romano mielodisplasie Italian regional database. J Clin Oncol 31(21):2671\u20132677. https:\/\/doi.org\/10.1200\/JCO.2012.48.0764","journal-title":"J Clin Oncol"},{"key":"6443_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.leukres.2018.01.022","volume":"67","author":"L de Swart","year":"2018","unstructured":"de Swart L, Smith A, Haase D, Fenaux P, Symeonidis A, Cermak J, Sanz G, Stauder R, Mittelman M, Hellstr\u00f6m-Lindberg E, Malcovati L, Langemeijer S, Skov-Holm M, M\u0105dry K, Germing U, Almeida AM, Tatic A, Savic A, \u0160imec NG, van Marrewijk C, Guerci-Bresler A, Sanhes L, Lu\u00f1o E, Culligan D, Beyne-Rauzy O, Burgstaller S, Blijlevens N, Bowen D, de Witte T (2018) Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDS. Leuk Res 67:21\u201326. https:\/\/doi.org\/10.1016\/j.leukres.2018.01.022","journal-title":"Leuk Res"},{"issue":"9","key":"6443_CR9","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.leukres.2005.01.019","volume":"29","author":"C Steidl","year":"2005","unstructured":"Steidl C, Steffens R, Gassmann W, Hildebrandt B, Hilgers R, Germing U, Tr\u00fcmper L, Haase D (2005) Adequate cytogenetic examination in myelodysplastic syndromes: analysis of 529 patients. Leuk Res 29(9):987\u2013993. https:\/\/doi.org\/10.1016\/j.leukres.2005.01.019","journal-title":"Leuk Res"},{"issue":"10","key":"6443_CR10","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1002\/ajh.25234","volume":"93","author":"CB Benton","year":"2018","unstructured":"Benton CB, Khan M, Sallman D, Nazha A, Nogueras Gonz\u00e1lez GM, Piao J, Ning J, Aung F, Al Ali N, Jabbour E, Kadia TM, Borthakur G, Ravandi F, Pierce S, Steensma D, DeZern A, Roboz G, Sekeres M, Andreeff M, Kantarjian H, Komrokji RS, Garcia-Manero G (2018) Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R. Am J Hematol 93(10):1245\u20131253. https:\/\/doi.org\/10.1002\/ajh.25234","journal-title":"Am J Hematol"},{"issue":"23","key":"6443_CR11","doi-asserted-by":"publisher","first-page":"4608","DOI":"10.1002\/cncr.30917","volume":"123","author":"J Neukirchen","year":"2017","unstructured":"Neukirchen J, Lauseker M, Hildebrandt B, Nolting AC, Kaivers J, Kobbe G, Gattermann N, Haas R, Germing U (2017) Cytogenetic clonal evolution in myelodysplastic syndromes is associated with inferior prognosis. Cancer 123(23):4608\u20134616. https:\/\/doi.org\/10.1002\/cncr.30917","journal-title":"Cancer"},{"issue":"3","key":"6443_CR12","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41408-018-0061-z","volume":"8","author":"J Schanz","year":"2018","unstructured":"Schanz J, Cevik N, Fonatsch C, Braulke F, Shirneshan K, Bacher U, Haase D (2018) Detailed analysis of clonal evolution and cytogenetic evolution patterns in patients with myelodysplastic syndromes (MDS) and related myeloid disorders. Blood Cancer J 8(3):28. https:\/\/doi.org\/10.1038\/s41408-018-0061-z","journal-title":"Blood Cancer J"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06443-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06443-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06443-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T18:14:05Z","timestamp":1757182445000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06443-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":12,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["6443"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06443-6","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"2 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent for participation was not required from the participants or the participants\u2019 legal guardians\/next of kin in accordance with the national legislation and institutional requirements.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The studies involving humans were approved by the Ethikkommission der Medizinischen Fakultaet der Heinrich Heine Universit\u00e4t Duesseldorf Votum 3973 Projekt MDS Register. The studies were conducted in accordance with the local legislation and institutional requirements. The human samples used in this study were acquired from a by-product of routine care or industry.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}